European Journal of Heart Failure

Papers
(The H4-Index of European Journal of Heart Failure is 49. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Association of preoperative infections, nasal Staphylococcus aureus colonization and gut microbiota with left ventricular assist device outcomes1191
Diabesity and heart failure with preserved ejection fraction: the picture is getting clearer824
Morphine in acute pulmonary oedema: a signal of harm but more questions than answers220
Carbohydrate antigen 125 concentrations across the ejection fraction spectrum in chronic heart failure: The EMPEROR programme208
May 2023 at a glance: focus on pathophysiology, comorbidities and devices189
Issue Information158
Letter regarding the article ‘Bending oxygen saturation index and risk of worsening heart failure events in chronic heart failure’136
Reply to ‘Morphine use in acute cardiogenic pulmonary oedema: is MIMO trial enough to change practice?’112
Issue Information110
Implementation of guideline‐recommended therapies in heart failure with reduced ejection fraction according to heart failure duration: An analysis of 55 581 patients from the Swedish Heart Failure (109
Revascularization and outcomes in ischaemic left ventricular dysfunction after heart failure admission: The RevascHeart study107
Can we trust a smartwatch ECG? Potential and limitations106
October 2023 at a glance: From prevention to diagnosis, prognosis and treatment of acute decompensation and comorbidities106
From prediction to prevention: The role of heart failure risk models100
What's all the fuss about a new guideline?94
Designing clinical trials in heart failure with preserved ejection fraction: quality over quantity?93
Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE‐MI): design and baseline characteristics92
Heart failure: age is no excuse for complacency91
Combination diuretic therapy for acute heart failure: ‘alone we can do so little; together we can do so much’89
83
Spironolactone, fibrosis and heart failure with preserved ejection fraction82
Plasma markers to risk stratify for heart failure in atrial fibrillation81
September 2022 at a glance81
Improving exercise tolerance and quality of life in heart failure with preserved ejection fraction – time to think outside the heart80
Early changes in renal function after sodium–glucose cotransporter 2 inhibitor initiation in EMPEROR‐Reduced: the end of the dilemma?79
Issue Information77
Reply to ‘Digoxin and beta‐blockers in patients with heart failure’. Letter regarding the article ‘Clinical outcomes with digoxin vs. beta‐blocker for heart rate control in permanent atrial fibrillati76
Issue Information76
Moving forwards from clinical trials to a more individualized management of treatments in heart failure? Great value of Doppler echocardiography data75
Quality over quantity: Assessing the need for multiple biomarkers in predicting heart failure outcomes75
Optimizing heart rate with ivabradine in heart failure with reduced ejection fraction: Insights from a post‐hoc analysis of the SHIFT trial71
The frail patient and the frailing heart. Letter regarding the article ‘Barcelona Bio‐HF calculator version 3.0: recalibration and incorporation of sodium–glucose cotransporter 2 inhibitor 70
Exercise left atrial compliance: One more tool in the heart failure with preserved ejection fraction assistance toolbox?70
Comprehensive vasodilatation in women with acute heart failure: Novel insights from the GALACTIC randomized controlled trial68
Change in ejection fraction and long‐term mortality in adults referred for echocardiography68
N‐terminal pro‐B‐type natriuretic peptide post‐discharge monitoring in the management of patients with heart failure and preserved ejection fraction – a randomized trial: The NICE study67
Clinical effect of obesity on N‐terminal pro‐B‐type natriuretic peptide cut‐off concentrations for the diagnosis of acute heart failure65
Reply to ‘Vericiguat in heart failure with reduced ejection fraction: the right choice above all else? The answermay lie in time’64
Can biomarkers help find the ‘sweet spot’ for treating patients with diabetes?63
Issue Information61
Letter regarding the article ‘Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure’60
Issue Information57
Blood pressure and intensive treatment up‐titration after acute heart failure hospitalization: Insights from the STRONG‐HF trial56
Cardiac immune‐related adverse events: an immune‐cardio‐oncology puzzle56
Expansion of the National Amyloidosis Centre staging system to detect early mortality in transthyretin cardiac amyloidosis54
Metabolic dysfunction and incidence of heart failure subtypes among Black individuals: The Jackson Heart Study52
Provocative testing in the evaluation of heart failure with preserved ejection fraction: Not all stresses are created equal52
Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction: early results of the REBALANCE‐HF trial roll‐in cohort51
Issue Information49
0.121502161026